|
Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. |
|
|
Honoraria - Apeiron Biologics; EUSA Pharma |
Consulting or Advisory Role - Apeiron Biologics; EUSA Pharma |
Research Funding - Apeiron Biologics |
Patents, Royalties, Other Intellectual Property - CellAct Pharma |
Travel, Accommodations, Expenses - EUSA Pharma |
|
Dominique Valteau-Couanet |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - EUSA Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Astellas Oncology; EUSA Pharma; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma |
Consulting or Advisory Role - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma (Inst) |
Research Funding - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Expert Testimony - Apeiron Biologics; EUSA Pharma |
Travel, Accommodations, Expenses - Apeiron Biologics; EUSA Pharma |